bioMrieux's consolidated sales rose to '1134 million for the first six months of 2017, up from '1001 million in the same period one year earlier. This represents growth of 13.3 percent, including a positive currency effect of around '21 million. Year-on-year organic growth came to 11.3 percent, led by the balanced contribution of both BioFire FilmArray on the one hand and the bioMrieux strategic lines on the other.

The gross profit for the first six months of the year came to '605 million or 53.3 percent of sales, up from 51.8 percent in the prior-year period. Gross margin benefited from a positive currency effect, strong growth in volumes, and an improvement in the product mix, with the BioFire FilmArray product line making a growing contribution. These positive effects more than offset the increase in depreciation relating to the commissioning of certain capital projects at several production sites.

Consolidated net debt amounted to '280 million on June 30, 2017, versus '275 million on December 31, 2016.
The company has issued '300 million in bonds maturing in October 2020, and holds an undrawn syndicated line of credit for '500 million maturing on January 26, 2022, with options to extend the facility for two additional years.

 'In light of this dynamic performance, as well as the more-favorable-than-expected currency environment, we are able to revise our full-year financial targets upward while pursuing our innovation and development efforts for the long term.'

Alexandre Mrieux




Digital version

Stay updated on
Medical Equipment
and Devices industry

Recieve our Daily Newsletter for free